Metabonomics Identifies Serum Metabolite Markers of Colorectal Cancer

Binbin Tan,Yunping Qiu,Xia Zou,Tianlu Chen,Guoxiang Xie,Yu Cheng,Taotao Dong,Linjing Zhao,Bo Feng,Xiaofang Hu,Lisa X. Xu,Aihua Zhao,Menghui Zhang,Guoxiang Cai,Sanjun Cai,Zhanxiang Zhou,Minhua Zheng,Yan Zhang,Wei Jia
DOI: https://doi.org/10.1021/pr400337b
2013-01-01
Journal of Proteome Research
Abstract:Recent studies suggest that biofluid-based metabonomics may identify metabolite markers promising for colorectal cancer (CRC) diagnosis. We report here a follow-up replication study, after a previous CRC metabonomics study, aiming to identify a distinct serum metabolic signature of CRC with diagnostic potential. Serum metabolites from newly diagnosed CRC patients (N = 101) and healthy subjects (N = 102) were profiled using gas chromatography time-of-flight mass spectrometry (GC-TOFMS) and ultraperformance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS). Differential metabolites were identified with statistical tests of orthogonal partial least-squares-discriminant analysis (VIP > 1) and the Mann Whitney U test (p < 0.05). With a total of 249 annotated serum metabolites, we 14 were able to differentiate CRC patients from the healthy controls using an orthogonal partial least-squares-discriminant analysis (OPLS-DA) in a learning sample set of 62 CRC patients and 62 matched healthy controls. This established model was able to correctly assign the rest of the samples to the CRC or control groups in a validation set of 39 CRC patients and 40 healthy controls. Consistent with our findings from the previous study, we observed a distinct metabolic signature in CRC patients including tricarboxylic acid (TCA) cycle, urea cycle, glutamine, fatty acids, and gut flora metabolism. Our results demonstrated that a panel of serum metabolite markers is of great potential as a noninvasive diagnostic method for the detection of CRC.
What problem does this paper attempt to address?